LATEST NEWS

Patients with rare, incurable digestive tract cancers respond to new drug combination

(November 19, 2018)

Dublin, Ireland: Patients with rare, but incurable cancers of the digestive tract have responded well to a combination of two drugs that block the MEK and BRAF pathways, which drive the disease in some... Continue Reading

Tivozanib for Renal Cell Cancer

(November 16, 2018)

The precision cancer medicine tivozanib delays cancer progression and prolongs survival in individuals with advanced renal cell cancer (RCC). About tivozanib Tivozanib is an oral vascular endothelial growth... Continue Reading

Keytruda Immunotherapy for Treatment of Liver Cancer

(November 13, 2018)

According to the results of a study presented at the recent gastrointestinal cancer symposia, Keytruda (pembrolizumab) is an active treatment for advanced liver cancer in patients who have already been... Continue Reading

U.S. Food and Drug Administration Approves Empliciti® Plus Pomalidomide to Treat Certain Patients with Relapsed or Refractory Multiple Myeloma

(November 12, 2018)

The U.S. Food and Drug Administration (FDA) has approved Empliciti (elotuzumab) injection for intravenous use in combination with pomalidomide and dexamethasone (EPd) for the treatment of adult patients... Continue Reading

REFERENCE AND TOOLS
LOCATIONS
Jackson Oncology Associates, PLLC
The Hederman Cancer Center
1227 North State Street, Suite 101
Jackson, MS 39202
TEL: (601)355-2485
FAX: (601)353-1463
Click Here for Map

Jackson Oncology Associates, PLLC
2368 Grove Street
Vicksburg, MS 39180
TEL: (601)638-3447
FAX: (601)630-9227
Click Here for Map
Jackson Oncology Associates, PLLC
St. Dominic Cancer Center
2969 Curran Drive North, Suite 200
TEL: (601)974-5600
FAX: (601)974-5699
Click Here for Map



Jackson Oncology Associates, PLLC
King's Daughters Hospital
427 Highway 51 North
Brookhaven, MS 39601
TEL: (601)355-2495
Click Here for Map